Woodline Partners »

Bicara Therapeutics shares owned by Woodline Partners

Quarter-by-quarter ownership of Bicara Therapeutics shares owned by Woodline Partners from 13F filings

Historical chart of Woodline Partners investment in Bicara Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Bicara Therapeutics held by Woodline Partners consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Bicara Therapeutics by Woodline Partners

Quarter filed Position value Share count Share price at filing
2024-09-30 $7.1M 278k 25.47

More positions owned by Woodline Partners

Meta Platforms Cl A (META)
Gilead Sciences (GILD)
Abbvie (ABBV)
Revolution Medicines (RVMD)
Vaxcyte (PCVX)
Asml Holding N V N Y Registry Shs (ASML)
Nuvalent Inc-a (NUVL)
Permian Resources Corp Class A Com (PR)
Encana Corporation (OVV)
Keysight Technologies (KEYS)
Danaher Corporation (DHR)
Aon Shs Cl A (AON)
Stmicroelectronics N V Ny Registry (STM)
Regeneron Pharmaceuticals (REGN)
EQT Corporation (EQT)

View all positions for Woodline Partners

Top funds holding Bicara Therapeutics

RA Capital Management
Siren
Tpg Gp A
Deerfield Management Company
Braidwell
T. Rowe Price Associates
Fairmount Funds Management
Baker Bros. Advisors
Blackstone Group
First Turn Management
Vestal Point Capital
Point72 Asset Management
Woodline Partners
OrbiMed Advisors
Citadel Advisors

View all funds holding Bicara Therapeutics